External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras.

UNLABELLED Detection of a new or recurrent breast cancer lesion relies on physical examination and imaging studies, primarily mammography, followed by histopathologic evaluation of biopsy tissue for morphologic confirmation. Approximately 66%-85% of detected lesions are not malignant. Therefore, biopsies are unnecessary for at least two thirds of patients. Human estrogen receptor-positive breast cancer cells typically display an elevated level of cyclin D1 protein because of the overexpression of CCND1 messenger RNA (mRNA) and an elevated level of insulin-like growth factor 1 (IGF1) receptor (IGF1R) because of the overexpression of IGF1R mRNA. We hypothesized that scintigraphic detection of CCND1 peptide nucleic acid (PNA) hybridization probes with a (99m)Tc-chelating peptide on the N terminus and an IGF1 peptide loop on the C terminus could detect CCND1 mRNA in human MCF7 breast cancer xenografts in nude mice from outside the body. METHODS We prepared the CCND1 probes as well as mismatched controls by solid-phase synthesis. We used fluorescence microscopy to detect the cellular uptake of fluoresceinyl probes and quantitative reverse transcription-polymerase chain reaction to detect the hybridization of probes to mRNA. We imaged (99m)Tc-probes in MCF7 xenografts scintigraphically and measured distribution by scintillation counting of dissected tissues. RESULTS IGF1R-overexpressing MCF7 cells internalized the fluorescein-chelator-CCND1 PNA-IGF1 peptide but not the mismatched control peptide. The chelator-CCND1 PNA-IGF1 peptide but not the control peptide lowered the level of cyclin D1 protein in IGF1R-overexpressing MCF7 xenografts in nude mice after intratumoral injection. IGF1R-overexpressing MCF7 xenografts in nude mice were visualized at 4, 12, and 24 h after tail vein administration of the (99m)Tc-CCND1 antisense probe but not the control probe. (99m)Tc-chimeras were distributed normally in the kidneys, liver, tumors, and other tissues. CONCLUSION Cancer gene activity can be detected from outside the body by probing with radionuclide-chelator-PNA-peptide chimeras.

[1]  I. Bièche,et al.  Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays , 2002, British Journal of Cancer.

[2]  S. Andò,et al.  Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. , 2001, Cancer research.

[3]  W. Talbot,et al.  Targeted gene knockdown in zebrafish using negatively charged peptide nucleic acid mimics , 2003, Developmental dynamics : an official publication of the American Association of Anatomists.

[4]  R. Jain.  The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.

[5]  P. Iversen,et al.  Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. , 1997, Journal of hematotherapy.

[6]  J. Carroll,et al.  A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence* , 2000, The Journal of Biological Chemistry.

[7]  Peter E. Nielsen,et al.  PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules , 1993, Nature.

[8]  A. Brandes,et al.  Positive predictive value of 99mTc sestamibi scintimammography in patients with non-palpable, mammographically detected, suspicious, breast lesions , 2002, Nuclear medicine communications.

[9]  G. Damonte,et al.  Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. , 2000, Cancer research.

[10]  E. Wickstrom,et al.  99mTc‐peptide‐peptide nucleic acid probes for imaging oncogene mRNAs in tumours , 2003, Nuclear medicine communications.

[11]  E. Wickstrom,et al.  Differential oligonucleotide activity in cell culture versus mouse models. , 1997, Ciba Foundation symposium.

[12]  G. Landberg,et al.  Cyclin‐D1 expression in human renal‐cell carcinoma , 1999, International journal of cancer.

[13]  E. Wickstrom,et al.  Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. , 1992, Cancer research.

[14]  P. Schneider,et al.  Cost-Benefit Analysis of Biopsy Methods for Suspicious Mammographic Lesions , 2001 .

[15]  E. Wickstrom,et al.  Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. , 1997, Bioconjugate chemistry.

[16]  J. Foekens,et al.  Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.

[17]  G. Sfakianakis,et al.  Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  M J O'Hare,et al.  Linking gene expression patterns to therapeutic groups in breast cancer. , 2000, Cancer research.

[19]  E. Wickstrom,et al.  Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. , 1997, Biochemical pharmacology.

[20]  J. S. Cohen,et al.  Oligonucleotides as therapeutic agents. , 1991, Pharmacology & therapeutics.

[21]  Jiang He,et al.  Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  D. Andrews,et al.  Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Bièche,et al.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.

[24]  E. Wickstrom,et al.  Imaging Oncogene Expression , 2003, Annals of the New York Academy of Sciences.

[25]  E. Wickstrom,et al.  Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Summerton,et al.  Morpholino antisense oligomers: design, preparation, and properties. , 1997, Antisense & nucleic acid drug development.

[27]  P. Nielsen,et al.  Progress in developing PNA as a gene-targeted drug. , 1997, Antisense & nucleic acid drug development.

[28]  Ű. Langel,et al.  Antisense properties of peptide nucleic acids. , 1999, Frontiers in bioscience : a journal and virtual library.

[29]  E. Wickstrom,et al.  Continuous solid-phase synthesis and disulfide cyclization of peptide-PNA-peptide chimeras. , 2002, Organic letters.

[30]  M. Thakur,et al.  99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  M. Thakur,et al.  Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  M. Stalteri,et al.  Hybridization and cell uptake studies with radiolabelled antisense oligonucleotides , 2001, Nuclear medicine communications.

[33]  M. Rusckowski,et al.  Electrostatic binding with tat and other cationic peptides increases cell accumulation of 99mTc-antisense DNAs without entrapment. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[34]  The Usefulness of MIBI Scanning to Detect Underlying Carcinoma in Women with Acute Mastitis , 2000, The breast journal.

[35]  F Diekmann,et al.  Evaluation of a wavelet‐based computer‐assisted detection system for identifying microcalcifications in digital full‐field mammography , 2004, Acta radiologica.

[36]  J. Smith,et al.  Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. , 1998, Journal of the National Cancer Institute.

[37]  M. Bergström,et al.  68Ga-labeled oligonucleotides for in vivo imaging with PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  P. Porcu,et al.  Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. , 1992, Cancer research.

[39]  S. Rattan,et al.  99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Surmacz.  Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor , 2003, Oncogene.